PRGO : Summary for Perrigo Company plc Ordinary Sh - Yahoo Finance

U.S. Markets closed

Perrigo Company plc (PRGO)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
73.94-0.07 (-0.09%)
At close: 4:02PM EDT
People also watch
MYLENDPALXNTEVAREGN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close74.01
Open74.02
Bid72.86 x 200
Ask74.98 x 200
Day's Range73.11 - 74.74
52 Week Range65.47 - 111.00
Volume1,385,482
Avg. Volume2,054,152
Market Cap10.6B
Beta0.62
PE Ratio (TTM)-7.34
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.64 (0.88%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cubeyesterday

    Perrigo Co. Plc – Value Analysis (NYSE:PRGO) : April 28, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Perrigo Co. Plc a score of 47. Our analysis is based on comparing Perrigo Co. Plc with the following peers – Catalent Inc, United Therapeutics Corporation, Valeant Pharmaceuticals International Inc and Daiichi Sankyo Company, Limited (CTLT-US, UTHR-US, VRX-US and DSKYF-US). Investment Outlook Perrigo Co. Plc has a ... Read more (Read more...)

  • Perrigo Co. Plc breached its 50 day moving average in a Bullish Manner : PRGO-US : April 27, 2017
    Capital Cube2 days ago

    Perrigo Co. Plc breached its 50 day moving average in a Bullish Manner : PRGO-US : April 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Perrigo Co. Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • The Wall Street Journal4 days ago

    [$$] Perrigo Reaches Agreement With Auditor Over Royalty Accounting

    Ernst & Young demanded the Dublin drugmaker adjust its accounting for the multiple sclerosis drug Tysabri after Perrigo sold the royalty rights in a deal worth as much as $2.85 billion.